Alcon and RxSight team up to develop light-adjustable cataract lenses
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/27/2026
- Wall Street ends mixed as investors focus on tech earnings
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices settle at lowest in over a week, as US pauses attacks on Iran
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- BuzzFeed cuts 35% of workforce in restructuring move
RxSight Inc. (RXST) PT Lowered to $6.50 at BofA Securities
July 7, 2026 12:24 PM EDTBofA Securities analyst Craig Bijou lowered the price target on RxSight Inc. (NASDAQ: RXST) to $6.50 (from $8.00) while maintaining a Underperform rating.
The analyst comments "RXST pre-Ad preliminary Q2 sales of $27m vs Street of $32m and lowered 2026 guidance by $13m at... More
